drugset / Trial / NCT05708274
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to investigate the short-term effects of 3 approved FDA drugs (cyproheptadine (CPH), carbidopa-levodopa (CD-LD), and atomoxetine (ATX)) on motor responses when delivered in combination with hand training exercises in people with chronic spinal cord injury. The goal is to learn how to better strengthen connections between the brain and spinal cord after spinal cord injury, and if this connection is improved by one(or more) of the drugs. Multiple aspects of nerve transmission and muscle response will be measured via noninvasive brain and spinal cord stimulation, along with motor performance (dexterity and strength).
Timeline
- Start
- 2023-01-20
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atomoxetine | Other / unclassified | 40 mg | Oral |
| Subject | Carbidopa | Unknown | 50 mg | Oral |
| Subject | Cyproheptadine | Small molecule | 8 mg | Oral |
| Subject | Levodopa | Small molecule | 200 mg | Oral |